pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT
Cogent Biosciences
Cogent Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker COGT. Primary therapeutic focus areas include Lymphoma, Gastrointestinal Stromal Tumors, Advanced Systemic Mastocy
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US HQ
2014 Founded
283 Employees
Public company Type
COGT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
- Founded
- 2014
- Employees
- 283
- Programs
- 13
- Drugs
- 8
- Patents
- 10
Bezuclastinib in combination with sunitinib
Phase 2 · small molecule · Gastrointestinal Stromal Tumors
Bezuclastinib in combination with sunitinib for Gastrointestinal Stromal Tumors is a Phase 2 program (small_molecule) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).
Internal code SARC044
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cogent Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Gastrointestinal Stromal Tumors
- Status
- active
- Trials
- 1